- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Eyepoint Pharmaceuticals Inc (EYPT)
Eyepoint Pharmaceuticals Inc stock price live, this page displays NASDAQ EYPT stock exchange data. View the EYPT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Eyepoint Pharmaceuticals Inc real time stock price chart below.
What Is the Eyepoint Pharmaceuticals Inc Stock Price Today?
The Eyepoint Pharmaceuticals Inc stock price today is 5.395.
What Is the Stock Symbol for Eyepoint Pharmaceuticals Inc?
The stock symbol for Eyepoint Pharmaceuticals Inc is "EYPT."
What Stock Exchange Does Eyepoint Pharmaceuticals Inc Trade On?
Eyepoint Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Eyepoint Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Eyepoint Pharmaceuticals Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EYPT quote. (ISIN: US30233G2093)
What Is the Eyepoint Pharmaceuticals Inc Stock Price Today?
The Eyepoint Pharmaceuticals Inc stock price today is 5.395.
What Is the Stock Symbol for Eyepoint Pharmaceuticals Inc?
The stock symbol for Eyepoint Pharmaceuticals Inc is "EYPT."
What Stock Exchange Does Eyepoint Pharmaceuticals Inc Trade On?
Eyepoint Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Eyepoint Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Eyepoint Pharmaceuticals Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EYPT quote. (ISIN: US30233G2093)
Fair Value
An estimate of a Eyepoint Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.295
6.290
52 wk Range
3.950
19.110
Unusual trading volume
1/2
Fair Value
An estimate of a Eyepoint Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.2956.290
52 wk Range
3.95019.110
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EYPT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Eyepoint Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
27.364
Upside
+406.73%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
RBC Capital cuts EyePoint stock rating on trial miss- Investing.com
pSivida Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
- pSivida Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
8 Buy
5 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 27.364
(+406.73% Upside)
Eyepoint Pharmaceuticals Inc Earnings Call Summary for Q1/2026
- EyePoint missed Q1 2026 forecasts with EPS of -$0.99 vs. -$0.82 expected; revenue fell 97.1% YoY to $0.7M as deferred revenue recognition ended.
- Operating expenses rose 20.5% to $88M driven by Phase III trials for DURAVYU; net loss widened to $85M from $45M in Q1 2025.
- Company maintains $223M cash position expected to fund operations through Q4 2027 without additional financing needs.
- DURAVYU Phase III wet AMD data expected mid-2026; DME trial enrollment to complete Q3 2026 as company pursues first-in-class treatment status.
- Stock rose 2.28% to $14.064 despite earnings miss, reflecting investor optimism about clinical pipeline despite high cash burn and regulatory risks.
Last Updated: 06/05/2026, 14:52
Read Full TranscriptEarnings
Latest Release
Aug 05, 2026
EPS / Forecast
-1.09 / -0.94
Revenue / Forecast
507K / 383K
Compare EYPT to Peers and Sector
Metrics to compare | EYPT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEYPTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −5.4x | −0.3x | |
PEG Ratio | 0.05 | −0.24 | 0.00 | |
Price/Book | 3.3x | 1.0x | 2.6x | |
Price / LTM Sales | 194.8x | 2.3x | 3.1x | |
Upside (Analyst Target) | 217.5% | 23.6% | 48.5% | |
Fair Value Upside | Unlock | 3.5% | 6.3% | Unlock |
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Eyepoint Pharma (EYPT) Stock Price Today?
The Eyepoint Pharma stock price today is 5.400 USD.
What Stock Exchange Does Eyepoint Pharma Trade On?
Eyepoint Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Eyepoint Pharma?
The stock symbol for Eyepoint Pharma is "EYPT."
What Is the Eyepoint Pharma (EYPT) Afterhours Price Today? (Afterhours variable test: 5.450) Current Date: Aug 20, 2026
After hours price: 5.450. After hours price change (units): 0.050. Price change percentage: 0.930%
What Is the Eyepoint Pharma Market Cap?
As of today, Eyepoint Pharma market cap is 475.030M USD.
What Is Eyepoint Pharma's Earnings Per Share (TTM)?
The Eyepoint Pharma EPS (TTM) is -3.764.
When Is the Next Eyepoint Pharma Earnings Date?
Eyepoint Pharma will release its next earnings report on Nov 04, 2026.
From a Technical Analysis Perspective, Is EYPT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Eyepoint Pharma Stock Split?
Eyepoint Pharma has split 2 times.
What is the current trading status of Eyepoint Pharma (EYPT)?
As of Aug 20, 2026, Eyepoint Pharma (EYPT) is trading at a price of 5.400 USD, with a previous close of 6.300 USD. The stock has fluctuated within a day range of 5.295 USD to 6.290 USD, while its 52-week range spans from 3.950 USD to 19.110 USD.
What Is Eyepoint Pharma (EYPT) Price Target According to Analysts?
The average 12-month price target for Eyepoint Pharma is 27.364 USD, with a high estimate of 68 USD and a low estimate of 5 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +406.73% Upside potential.
What Is the EYPT Premarket Price?
EYPT's last pre-market stock price is 6.170 USD. The pre-market share volume is 93,030.000, and the stock has decreased by -0.130, or -2.060%.
What Is the EYPT After Hours Price?
EYPT's last after hours stock price is 5.450 USD, the stock has decreased by 0.050, or 0.930%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.